Abstract:Abstract Background Pyrrolidine alkaloid‑induced hepatic sinusoidal obstruction syndrome (PA-HSOS) is a drug-induced liver injury characterized by sudden and rapidly progressive portal hypertension. Hepatic venous pressure gradient (HVPG) is the gold standard for the diagnosis of sinus hypertension, at least in viral and alcoholic liver disease, while its role in evaluating disease severity and treatment choice and predicting prognosis in patients with PA-HSOS needs further verification. The aim of this study was to investigate the clinical value of HVPG in patients with PA-HSOS. Methods Patients who were diagnosed with PA-HSOS according to the “Nanjing criteria” and received HVPG measurements in our hospital between January 2016 and April 2020 were reviewed retrospectively. Next, the predictive efficacy of HVPG in initial anticoagulant therapy, the prognostic survival of patients in different HVPG groups, the relationship between HVPG and the Drum Tower Severity Scoring (DTSS), the correlation between HVPG and pathological data were all evaluated. Results A total of 76 PA-HSOS patients were included in the study. Multivariate logistic regression analysis identified HVPG as independently associated with nonresponse to initial anticoagulation (95% CI: 1.006-1.413, P=0.043). The receiver operating characteristic curve (ROC) identified a cutoff value of 20.165 mmHg (sensitivity: 0.744, specificity: 0.697) for predicting nonresponse to initial anticoagulation, and the area under the curve (AUC) was 0.741 (95% CI: 0.626-0.857, P<0.001). When HVPG>20.165 mmHg was combined with serum total bilirubin (STB), heart rate (HR) and blood urea nitrogen (BUN) for modeling, the AUC was 0.881 (P<0.001). Seventy-six patients were divided into two groups according to whether HVPG was greater than 20.165 mmHg, and the patients in the high HVPG group (HVPG＞20.165 mmHg) had a significantly worse prognostic survival than the patients in the low HVPG group (HVPG＜20.165 mmHg) (P=0.022, χ2=5.285). Additionally, there was a linear correlation between HVPG and the area of sinusoidal bleeding in 76 patients (P=0.008, R=0.343). Furthermore, after excluding the patients with an onset time of more than 1 month, HVPG improved the efficacy in predicting nonresponse to anticoagulant therapy (AUC=0.789, 95% CI: 0.654-0.924, P=0.001), and the linear relationship between HVPG and bleeding area in the sinusoids was enhanced (P=0.001, R=0.499). In addition, a linear relationship between HVPG and DTSS emerged (P<0.001, R=0.522). Conclusions HVPG can assist in predicting the outcome of anticoagulant therapy and prognosis in patients with PA-HSOS, and this prediction is more accurate for patients within one month of disease onset.

Expert Consensus on the Clinical Management of Pyrrolizidine Alkaloid‐induced Hepatic Sinusoidal Obstruction Syndrome

Hepatic Sinusoidal Obstruction Syndrome Caused by the Ingestion of Gynura Segetum in a Patient with Alcoholic Cirrhosis: a Case Report.

Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome.

Pyrrolizidine Alkaloids-Induced Hepatic Sinusoidal Obstruction Syndrome: Pathogenesis, Clinical Manifestations, Diagnosis, Treatment, and Outcomes

Prognostic Factors for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome: a Multicenter Study in China

Definitive Diagnosis of Hepatic Sinusoidal Obstruction Syndrome Induced by Pyrrolizidine Alkaloids.

Low Molecular Weight Heparin in the Treatment of Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome: Five Case Reports

Tusanqi and Hepatic Sinusoidal Obstruction Syndrome

Prognostic Risk Factors for Patients with Hepatic Sinusoidal Obstruction Syndrome Caused by Pyrrolizidine Alkaloids

Transjugular Intrahepatic Portosystemic Shunt for Pyrrolizidine Alkaloid-Related Hepatic Sinusoidal Obstruction Syndrome

Clinical Efficacy and Safety of Anticoagulation Therapy for Pyrrolizidine Alkaloids-Induced Hepatic Sinusoidal Obstruction Syndrome: a Retrospective Multicenter Cohort Study

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

[Clinical Characteristics of Hepatic Sinusoidal Obstruction Syndrome: Analysis of 8 Cases].

Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features.

Clinical features of sinusoidal obstruction syndrome induced by pyrrolidine alkaloids in China

The value of hepatic venous pressure gradient in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome

Blood Pyrrole-Protein Adducts As A Diagnostic and Prognostic Index in Pyrrolizidine Alkaloid-Hepatic Sinusoidal Obstruction Syndrome

Diagnostic Performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome

Gynura segetum induces hepatic sinusoidal obstruction syndrome in a child: A case report

Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study

Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by Gynura japonica Containing Pyrrolizidine Alkaloids